Antivenomics and Ophidic Accident Treatment in Guatemala: A MiniReview

Snakebite envenoming remains a significant public health concern in Central America, particularly in rural and agricultural communities where snakebite incidents are frequent and access to medical care is often limited. This mini-review examines the current state of snakebite management in the region, with a particular emphasis on Guatemala, where approximately 849 cases are reported annually according to official sources. Epidemiological data from the Ministry of Health indicate that the departments of Petén, Alta Verapaz, and Izabal are the most affected. Compiled data demonstrate that males aged 5 to 30 years experience the highest incidence of snakebites, primarily related to agricultural and outdoor activities. Medically significant snake species, mainly from the genera Bothrops, Crotalus, and Micrurus, are responsible for severe clinical manifestations, including local tissue damage, systemic hemorrhage, and neurotoxicity. Antivenom therapy remains the only treatment but faces persistent challenges, such as limited accessibility, geographic variation in venom composition, and logistical challenges in distribution and storage. In Guatemala, antivenoms are predominantly supplied by international producers (Instituto Clodomiro Picado, Costa Rica; Bioclon, Mexico; and Instituto Biológico Argentino, Argentina), although their efficacy varies due to differences in venom immunogenicity, which complicates standardized treatment. This mini-review underscores the importance of addressing snakebite envenoming as a neglected tropical disease and identifies the urgent need for area-specific antivenom development, improved medical infrastructure, community education, and enhanced epidemiological surveillance. Special attention is given to Guatemala’s unique challenges, including misinformation, delayed medical attention, and insufficient treatment availability within the public health system.